Product
Enoxaparin
Aliases
Clexane, Dalteparin, Enoxaparin Injectable Solution, Enoxaparin sodium (5 other aliases)
Name
Enoxaparin Sodium
INN Name
Enoxaparin Sodium
FDA Approved
Yes
37 clinical trials
6 organizations
46 indications
2 documents
Indication
Knee ArthroplastyIndication
TotalIndication
Venous ThromboembolismIndication
Pulmonary EmbolismIndication
Thrombotic DiseaseIndication
ThromboembolismIndication
BleedingIndication
Safety IssuesIndication
Drug EffectIndication
Respiratory InsufficiencyIndication
Cardiogenic ShockIndication
COVID-19Indication
Arterial ThrombosisIndication
ThrombosisIndication
Leg InjuryIndication
Varicose VeinsIndication
Cancer-associated ThrombosisIndication
ThrombocytopeniaIndication
Recurrent Pregnancy LossIndication
Antiphospholipid SyndromeIndication
Pediatric Kidney Transplant RecipientsIndication
Spinal Cord InjuriesIndication
Spinal DiseasesIndication
HemorrhageIndication
Intensive CareIndication
Anastomotic LeakageIndication
Lymph Node DiseaseIndication
SurvivalIndication
Transfusion, BloodIndication
Deep Vein ThrombosisIndication
pulmonary embolismIndication
Anticoagulants and Bleeding DisordersIndication
SurgeryIndication
Regional Anesthesia MorbidityIndication
Intrauterine Growth RestrictionIndication
Premature BirthIndication
pre-eclampsiaIndication
Ovarian CancerIndication
Critical IllnessIndication
ST Elevation Myocardial InfarctionIndication
nephrotic syndromeIndication
PsoriasisIndication
ThromboprophylaxisIndication
Connective Tissue DiseasesIndication
Pregnancy RelatedClinical trial
An Open, Randomized, Active-comparator-controlled, Multicenter Study to Assess the Efficacy and Safety of Different Doses of KN060 for the Prevention of Venous Thromboembolism in Patients Undergoing Unilateral Total Knee Arthroplasty.Status: Recruiting, Estimated PCD: 2025-12-15
Clinical trial
A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism After Elective, Unilateral, Total Knee ArthroplastyStatus: Active (not recruiting), Estimated PCD: 2024-05-29
Clinical trial
A Multicenter, Randomized, Active-comparator-controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of a Single Subcutaneous Injection of SHR-2004 in Patients Undergoing Elective Unilateral Total Knee ArthroplastyStatus: Recruiting, Estimated PCD: 2024-06-15
Clinical trial
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b When Added to Standard of Care Anticoagulation Therapy in Subjects With Acute Submassive Pulmonary EmbolismStatus: Completed, Estimated PCD: 2019-08-05
Clinical trial
Evaluation of the Factor Xa Inhibitor, PRT054021, Against Enoxaparin in a Randomized Trial for the Prevention of Venous Thromboembolic Events After Unilateral Total Knee Replacement (EXPERT)Status: Completed, Estimated PCD: 2007-01-01
Clinical trial
(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill PatientsStatus: Completed, Estimated PCD: 2015-12-01
Clinical trial
A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Second Generation Andexanet Alfa Administered to Healthy SubjectsStatus: Completed, Estimated PCD: 2017-09-28
Clinical trial
Non-ST-Segment Elevation Acute Coronary Syndrome (NSTEACS) Patients in Multicenter, Non-randomized, Open-label, Non-inferiority TrialStatus: Recruiting, Estimated PCD: 2023-11-30
Clinical trial
A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 PatientsStatus: Completed, Estimated PCD: 2022-03-10
Clinical trial
A Three-arm Randomized Controlled Non-inferiority Pilot Study Comparing Anticoagulation Strategies Using Unfractionated Heparin, Argatroban and Low-molecular-weight Heparin for Extracorporeal Membrane Oxygenation SupportStatus: Recruiting, Estimated PCD: 2026-07-30
Clinical trial
Thromboprophylaxis in Lower Limb Immobilisation (TiLLI): a Multicentre Study Comprising Two Linked Open Label Phase III Randomised Controlled Trials Evaluating the Effectiveness and Cost Effectiveness of Different Methods of Pharmacological Prophylaxis for Patients With Temporary Lower Limb Immobilisation.Status: Not yet recruiting, Estimated PCD: 2028-02-01
Clinical trial
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) - a Multi-centre Assessor-blind Randomised-controlled TrialStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated ThrombosisStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Use of Warfarin After the First Trimester in Pregnant Women With Antiphospholipid SyndromeStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant RecipientsStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord InjuryStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy In Right Cancer Colon Patients: A Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2026-01-02
Clinical trial
InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19: A Prospective Randomized Study (The IMPACT Trial)Status: Terminated, Estimated PCD: 2021-04-17
Clinical trial
Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic TraumaStatus: Completed, Estimated PCD: 2019-06-30
Clinical trial
Evaluation of Residual Anti-Xa Activity As A Function Of Time Following The Last Treatment Dose of Enoxaparin In Patients Presenting For Elective SurgeryStatus: Terminated, Estimated PCD: 2022-01-14
Clinical trial
Enoxaparin at Prophylactic or Therapeutic Doses With Monitoring of Outcomes in Subjects Infected With COVID-19: a Pilot Study on 300 Cases Enrolled at ASST-FBF-SaccoStatus: Completed, Estimated PCD: 2022-10-16
Clinical trial
A Pilot Randomized Controlled Trial of Low Molecular Weight Heparin or no Treatment Following Cesarean DeliveryStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Low Molecular Weight Heparin for the Treatment of Early Fetal Growth RestrictionStatus: , Estimated PCD: 2024-12-30
Clinical trial
Age-dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-associated Thrombosis in Critically Ill ChildrenStatus: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims DataStatus: Completed, Estimated PCD: 2021-07-21
Clinical trial
Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSEStatus: Completed, Estimated PCD: 2021-04-29
Clinical trial
Postpartum Heparin Against Venous Thromboembolism: a Pilot Randomized Controlled TrialStatus: Completed, Estimated PCD: 2023-03-13
Clinical trial
Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.Status: Completed, Estimated PCD: 2021-08-31
Clinical trial
FREEDOM COVID Anticoagulation Strategy Randomized TrialStatus: Completed, Estimated PCD: 2022-12-30
Clinical trial
A Randomized Controlled Trial Comparing Apixaban Versus Enoxaparin Following Microsurgical Breast ReconstructionStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Randomized Comparison of Anticoagulation After Primary Percutaneous Coronary Intervention Using Enoxaparin, ACT Guided Unfractionated Heparin or Bivalirudin Prolongation vs. no Anticoagulation To Improve Clinical OutcomeStatus: Completed, Estimated PCD: 2022-11-23
Clinical trial
Assessment of Coagulation Disorders and of Enoxaparin's Anti-Xa Activity, When Used for Thromboprophylaxis, in Severe Nephrotic Syndrome.Status: Terminated, Estimated PCD: 2018-11-30
Clinical trial
The Efficacy of Low-Dose Enoxaparin in PsoriasisStatus: Not yet recruiting, Estimated PCD: 2024-09-01
Clinical trial
Anti-Xa Concentrations With Continuous Intravenous Infusion and Subcutaneous Administration of Enoxaparin After Coronary Artery Bypass Grafting: Randomized Clinical TrialStatus: Completed, Estimated PCD: 2023-03-31
Clinical trial
The Clinical Features and Pregnancy Outcomes of Patients With Connective Tissue Disease :a Prospective Cohort StudyStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase 2, Multicenter, Randomized, Open-Label, Active Control Study of REGN7508, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism After Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II)Status: Not yet recruiting, Estimated PCD: 2025-03-26
Organization
Fresenius Kabi USA, LLC
Organization
Cardinal Health 107, LLCOrganization
Amphastar Pharmaceuticals, Inc.Document
DailyMed Label: LovenoxOrganization
Sanofi-Aventis U.S. LLCOrganization
Meitheal Pharmaceuticals Inc.Organization
Italfarmaco SpA